BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsFDA / regulatory

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus’ differentiated pipeline and leadership in eye care IRVINE, Calif.,

Related news

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-07-08 20:05 EST

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

HROWHarrow, Inc.2026-10-05 11:00 EST

Harrow Closes Acquisition of TYRVAYA®

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

RHHBYRoche Holdings AG2026-09-10 05:00 EST

U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments

OTLKOutlook2026-07-24 18:40 EST

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

OKYOOKYO Pharma2026-07-08 11:00 EST

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

OTLKOutlook2026-08-14 11:15 EST

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

TARSTarsus Pharmaceuticals2026-09-04 12:39 EST

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

TARSTarsus Pharmaceuticals2026-09-01 20:30 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Stock data

Close
74.11 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States